Search

In 2022, the activity of biotech companies in Spain generated more than 16.6 billion euros in revenue, representing 1.5% of the national GDP. Private funding raised by the sector reached an all-time

Biotechnology is central to the diagnosis, treatment and follow-up of prostate cancer and plays a broad role across the spectrum of patient care. Telomere measurement technology represents a useful

Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions. Biofuels are one of

AseBio has organized, within the framework of the XVII Annual Conference of Biomedical Research Technology Platforms (Barcelona), the debate entitled “Collaboration and transfer: the DNA of biomedical

Biotechnology is a cornerstone for the agri-food industry and for transforming food systems, as well as for addressing the underlying causes of food security and malnutrition. Thanks to precision

During the celebration of the AseBio Investor Day 2024, several experts analyzed the challenges and opportunities of the bioeconomy sector in Spain. Since 2010, as part of the Europe 2020 Strategy

During the AseBio Investor Day, held on May 15th in San Sebastián, AseBio has revealed data on private financing collected in the AseBio 2023 Report. The AseBio 2023 Report, a leading publication in

Biotechnology has achieved significant advances in diagnosis and precision therapies, the production of biotechnological drugs, and the treatment and understanding of infectious, autoimmune, and

Next-generation DNA sequencing has a significant impact on personalized medicine, genomic research, and the identification of genetic diseases. Genomic medicine is emerging as a central pillar of the

The Spanish agri-food sector has undeniable strategic value for the national economy due to its impact on GDP: Spain ranks as the eighth global agri-food power. Within AseBio, over 25% of our members

We consider that improvements have been made regarding the original proposal, but these continue to be insufficient for the protection, development, and promotion of biotechnological innovation in

Approximately 10,000 new cases of Parkinson's are detected each year in Spain, with a total figure exceeding 150,000 individuals. Parkinson's is an extremely debilitating disease, there is no cure

AseBio's health pipeline includes 130 molecules for 150 indications being researched by 40 national companies, with oncology as the majority area. Spain stands out as one of the leading countries in

Humanity is at a critical moment for its future, with the need to promote more sustainable economic models that respond to social and environmental challenges. Biotechnology provides solutions through

Blue biotechnology is positioned as one of the emerging sectors within the so-called Blue Economy, a key element for the European Commission to achieve goals such as those outlined in the European

The current scenario shows a worrying bottleneck with a detriment to innovative biotech products, indefinitely delaying their access to the market. Currently in Europe only 12 conformity assessment

With the creation of this commercial corporation, it is expected to "bring two advanced therapies to authorization and commercialization in 2027 manufactured in Spain." The Spanish biotech industry is

The future Deep Tech Strategy takes up the challenge of the proposal for the creation of a High Commissioner for Deep Strategic Technologies made jointly by the four entities. We consider that the

AseBio organizes the event "Women in Biotech for Better Science and Innovation," highlighting the significant role of women in the biotechnology industry. In addition, the names of professional women

In Spain, around three million people live with rare diseases or are in search of a diagnosis. Only 20% of the over 6,300 rare diseases identified in Europe are currently under investigation. In

Belén Diego is a contributor to Diariofarma and correspondent for APM Health Europe in Spain and Portugal, while Miguel Sanmartín is the founder of Capital Radio and host of the program 'Biotecnología